Background With recent advances in different breast cancer treatment modalities, breast conservation surgery (BCS) has gained popularity and has become the mainstay for the treatment of early breast cancer. The model of dedicated breast surgeons working in breast units is standard in some but not all countries. We have aimed to define surgical outcomes of oncoplastic breast surgery carried out by one general surgical oncologist. Patients and methods We have conducted a prospective non-randomised case series analysis to assess the oncologic and aesthetic outcome of tissue displacement oncoplastic breast techniques in managing unifocal early-stage breast cancer from January 2019 to January 2020. One surgical oncologist with 23 years of surgical oncology experience carried out all operations. Results We have included 50 female patients treated with variant oncoplastic volume displacement techniques. We have used the round block technique in 20%, the batwing technique in 18%, lateral mammoplasty in 20%, and medial mammoplasty in 2%. We have also carried out wise pattern therapeutic mammoplasty with inferior pedicle in 20% (10 patients), and vertical mammoplasty with superior pedicle in 20% (10 patients). While 8% of our patients had Clavien-Dindo system grade I Immediate complications, including the surgical site infection and postoperative seroma and haematoma, 2% of patients had grade II complications in the form of partial areola and nipple complex necrosis leading to delayed wound healing requiring secondary suturing. No delayed complications or mortalities were recorded. Eight per cent of patients required re-excision to clear margins, 74% had excellent results, 24% had good results, and 2% had fair results. In addition, 64% were very satisfied with their results, 32% were satisfied, while 4% were not satisfied with aesthetic results. Conclusion Based on our limited number of patients, we have found that tissue displacement oncoplastic techniques carried out by a general surgical oncologist are safe and reliable in providing satisfactory oncological outcomes with a low risk of delaying adjuvant therapy and acceptable aesthetic outcomes.

Background: Pediatric ovarian tumors are rare. The aim of this work is to study the epidemiological characteristics and treatment outcome of these tumors in our locality. Methods: This retrospective study was performed in accordance with the ethical policies. Between January 2011 to December 2015, Thirteen cases of pediatric ovarian cancers were recorded in the Pediatric Oncology Unit of Oncology Center of Mansoura University and the Clinical Oncology & Nuclear Medicine Department of Mansoura University Hospital. The clinico-epidemiologic data and the treatment protocols were analyzed. Results: The median age was 10 years (range: 2-17). Presenting symptoms were mainly lower abdominal pain (6; 46.2%) and palpable abdominal mass (4; 30.7). Through laparotomy all patients underwent unilateral salpingo-oophorectomy except one case for whom bilateral salpingiooophorectomy was done. Six patients were stage I (46.2%), 2 patients were stage II (15.4%) and 5 patients were stage III tumors (38.4%). The majority had germ cell tumors (11; 85%). Adjuvant chemotherapy was given to all cases. Further chemotherapy was needed in 6 cases due to progression or recurrence. The median follow up was 35 months while the median overall survival was 40 months. Mortality rates were 90% in stages II and III together. The advanced stages and yolk sac pathology had the highest mortality. One of the survived cases got married and delivered a baby. Conclusion: Germ cell tumors are the commonest pediatric malignant ovarian tumors. Multimodality treatment is essential. Fertility preservation should be respected. Our mortality rates are relatively high.

Background: Ovarian tumors true incidence in young females is not known. Objective: To review the incidence of ovarian tumors in children and adolescents and their clinical presentation in these patients in Aswan city and district as representative of Egypt. We also characterized the pathological features of these ovarian tumors and tailor the best management of these tumors in young females(less than 18 years old). Patients and Methods: Thirty-six malignant ovarian tumors in females <18 years were followed in Surgery Department, Aswan University hospital. Different aspects were analyzed regarding clinicopathological data, investigations and treatment. Follow up by clinical examination, CT scan and laboratory profile was done every 3 months in the first year, then every 6 months in the second year and then yearly. The follow up period for each case was calculated from end of the treatment to the last follow up visit. Results: Thirty-six young female patients with malignant ovarian tumors were recorded, which represented 18% of total pediatric malignancy throughout the 3 years of the study. All patients underwent primary surgical resection through laparotomy. Unilateral salpingo-oophrectomy (USO) was performed. AFP was the commonest elevated marker in 6 cases and CA125 in 4 cases. The most common symptom was abdominal mass in 14 cases and most common tumor was yolk sac tumor 14 cases. All cases received chemotherapy adjuvantly except the four cases stage 1. However, due to progression and recurrence, six cases required further chemotherapy lines. Conclusion: Yolk sac tumor and dysgerminoma are the commonest pediatric malignant ovarian tumors in this study. Multimodality treatment is essential. Fertility preservation should be respected. The advanced stages have the highest mortality.

No abstract

Background The dual technique using blue dye in combination with a radioisotope is considered the gold standard for identifying sentinel lymph nodes (SLNs) in patients with breast cancer. Unfortunately, not all cancer centres have access to radioactive material, which jeopardizes the SLN identification rate and patient safety. Aim We aimed to assess the safety and efficacy of mitoxantrone hydrochloride injection (MHI) for identifying axillary SLNs in patients with primary breast cancer. Patients and methodsWe have conducted a prospective non-randomized analysis of patients diagnosed with invasive breast cancer who agreed to participate in the study between December 2019 and December 2022. We have used the patient's medical records to collect the data. We have used the SLN intraoperative identification rate as a marker for the efficacy of the technique and both the immediate and delayed complication rates and routine blood tests as markers for the safety of the technique. Results Out of the 296 patients, 289 (97.6%) had their SLNs identified using MHI, while seven patients (2.3%) had four-node sampling carried out because the SLNs were not identified. Liver functions were not significantly affected by MHI, and there was no technique-related readmission or reported morbidity or mortality. Conclusion We have found that the MHI technique is still inferior to the combined radioactive directed technique and patent blue V dye in SLN identification. Yet, it may serve as a safe and reliable alternative in cases where the radioactive technique is unavailable.